Maviret (Glecaprevir/Pibrentasvir)

Maviret (known as Mavyret in the United States) is a major breakthrough in the treatment of chronic hepatitis C virus (HCV) infections. Developed by the American biopharmaceutical company AbbVie, the medicine is a fixed-dose combination of two direct-acting antivirals: glecaprevir and pibrentasvir. This treatment is notable for its high efficacy rates and its ability to treat all major genotypes of hepatitis C.

While AbbVie is headquartered in the United States, the manufacturing of its specialized drug products like Maviret typically occurs across a global network of sophisticated facilities, including major sites in Ireland, Germany, and the United States. The brand remains under the exclusive ownership of AbbVie, which became an independent research-based biopharmaceutical company after spinning off from Abbott Laboratories in 2013.